BioMarin Pharmaceutical Inc. (BMRN), Wednesday announced positive data from the CANOPY clinical program evaluating Voxzogo in children with achondroplasia, a rare genetic skeletal condition, and other similar conditions.
The results revealed that children with achondroplasia treated with the prescription medicine experienced meaningful improvements beyond height, such as in health-related quality of life, and increased bone length while maintaining bone strength.
Also, additional results from investigator-led study noted sustained growth gains in children with hypochondroplasia, noonan syndrome and genetic variants associated with idiopathic short stature.
Currently, BioMarin's stock is trading at $71.47, up 1.26 percent on the Nasdaq.
For comments and feedback: editorial@rttnews.com